Wellington Management Group
RCKT icon

Wellington Management Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Wellington Management Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,626,491
Closed -$84.2M – 2031
2025
Q1 		$84.2M Sell
12,626,491
-1,368,686
-10% -$13.5M 0.02% 552
2024
Q4 		$176M Buy
13,995,177
+2,753,033
+24% +$41.4M 0.03% 394
2024
Q3 		$208M Buy
11,242,144
+2,086,424
+23% +$42.7M 0.04% 384
2024
Q2 		$197M Sell
9,155,720
-379
-0% -$8.71K 0.04% 383
2024
Q1 		$247M Buy
9,156,099
+958,553
+12% +$27.2M 0.04% 352
2023
Q4 		$246M Buy
8,197,546
+174,716
+2% +$3.86M 0.05% 356
2023
Q3 		$164M Buy
8,022,830
+2,880,373
+56% +$52.4M 0.03% 416
2023
Q2 		$102M Buy
5,142,457
+1,034,529
+25% +$20.9M 0.02% 539
2023
Q1 		$70.4M Buy
4,107,928
+600,911
+17% +$11.8M 0.01% 617
2022
Q4 		$68.6M Buy
3,507,017
+28,605
+0.8% +$527K 0.01% 609
2022
Q3 		$55.5M Buy
3,478,412
+72,283
+2% +$1.13M 0.01% 645
2022
Q2 		$46.9M Sell
3,406,129
-66,512
-2% -$793K 0.01% 695
2022
Q1 		$55.1M Sell
3,472,641
-18,238
-0.5% -$315K 0.01% 727
2021
Q4 		$76.2M Buy
3,490,879
+144,648
+4% +$3.95M 0.01% 706
2021
Q3 		$100M Sell
3,346,231
-871,744
-21% -$31.7M 0.02% 627
2021
Q2 		$187M Buy
4,217,975
+558,898
+15% +$24.3M 0.03% 458
2021
Q1 		$162M Buy
3,659,077
+977,556
+36% +$53.7M 0.03% 475
2020
Q4 		$147M Buy
2,681,521
+999,916
+59% +$36.5M 0.03% 485
2020
Q3 		$38.4M Sell
1,681,605
-7,385
-0.4% -$182K 0.01% 769
2020
Q2 		$35.4M Buy
1,688,990
+9,510
+0.6% +$171K 0.01% 786
2020
Q1 		$23.4M Sell
1,679,480
-86,165
-5% -$1.71M 0.01% 842
2019
Q4 		$40.2M Buy
1,765,645
+4,574
+0.3% +$76.4K 0.01% 818
2019
Q3 		$20.5M Buy
1,761,071
+1,405,203
+395% +$17.4M ﹤0.01% 954
2019
Q2 		$5.34M Buy
355,868
+82,972
+30% +$1.45M ﹤0.01% 1358
2019
Q1 		$4.79M Buy
+272,896
New +$4.31M ﹤0.01% 1387

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Wellington Management Group's RCKT Position: Q2 2025 in Review

Wellington Management Group sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 12,626,491 shares — an estimated $84.2M sold.

Wellington Management Group first reported a position in RCKT in Q1 2019 and held it in 25 quarters. The position peaked at $247M in Q1 2024. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Wellington Management Group reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Wellington Management Group sold 12,626,491 Rocket Pharmaceuticals shares in Q2 2025, an estimated $84.2M.
  • Wellington Management Group first reported a position in Rocket Pharmaceuticals in Q1 2019 and held it in 25 quarters.
  • Wellington Management Group's Rocket Pharmaceuticals position peaked at $247M in Q1 2024.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Wellington Management Group's 13F filing for Q2 2025, filed 14 Aug 2025.